CDO1 and non-small cell lung carcinoma: In addition, Ooki et al. described a serum-based gene signature, previously identified in tumors from TCGA (MARCH11, HOXA9, CDO1, UNCX, PTGDR, and AJAP1) that was able to differentiate stage I NSCLC patients from the controls, with 72.1% sensitivity and 71.4% specificity [62].